An open label, randomized study for the comparison of effectiveness between glucagon-like peptide-1 (GLP-1) analogue in people with type 2 diabetes treated bolus first or basal first insulin therapy

INTERVENTION: Liraglutide 0.9mg once a day for 6 months after treating fasting blood glucose with Bolus First(insulin glulisine)insulin therapy Exenatide 10ug twice a day for 6 months after treating fasting blood glucose with Bolus First(insulin glulisine)insulin therapy Liraglutide 0.9mg once a day for 6 months after treating fasting blood glucose with Basal First(insulin glargine)insulin therapy Exenatide 10ug twice a day for 6 months after treating fasting blood glucose with Basal First(insulin glargine)insulin therapy CONDITION: Type 2 diabetes PRIMARY OUTCOME: insulin dose to safely switch to GLP‐1 analogue INCLUSION CRITERIA: The subjects must satisfy the following conditions: 1)Age at the time of obtaining informed consentis more than 20 years old 2) Patients with type 2 diabetes, whose HbA1c is more than 7.4% 3) Gender is unquestioned 4) Patients treated with Bolus First or Basal First insulin therapy